Rare Cancers Face Disproportionate Research Funding Gaps, Expert Warns
Antonio Lázaro Sánchez, a researcher at Spain’s National Cancer Research Centre (CNIO), has called for urgent action to address the underfunding of rare cancers, which account for 20% of all cancer cases but receive less than 5% of global research investment, according to the National Cancer Institute (NCI).
Why Are Rare Cancers Overlooked in Research?
Rare cancers—defined as those affecting fewer than 15 in 100,000 people—often lack the commercial incentives and large patient pools that drive research for more common malignancies like breast or lung cancer. “The focus on high-prevalence cancers creates a ‘second-class’ status for rare diseases, limiting treatment options for patients,” Lázaro Sánchez said in a recent statement.
Funding Disparities Highlight Systemic Gaps
Data from the NCI reveals that while rare cancers make up 20% of all cancer diagnoses, they receive less than 5% of research funding. The European Society for Medical Oncology (ESMO) echoes this concern, noting that only 2% of clinical trials target rare cancers. “This gap perpetuates poorer outcomes for patients, as therapies are often developed for more common cancers first,” said Dr. Maria García, a senior oncologist at the Spanish National Cancer Centre.
New Initiatives Aim to Bridge the Divide
Recent efforts, such as the National Institutes of Health’s (NIH) Rare Diseases Clinical Research Network, seek to prioritize rare cancer studies. The network’s 2023 report highlighted a 30% increase in rare cancer research funding over the past five years, though advocates argue more is needed. “We need policies that mandate equitable funding and collaboration across institutions,” Lázaro Sánchez added.
What’s Next for Rare Cancer Research?
Experts emphasize that addressing the funding gap requires systemic change. The World Health Organization (WHO) recommends integrating rare cancer research into national health strategies, while patient advocacy groups push for greater public awareness. “Without urgent action, thousands of patients will continue to face limited treatment options,” said Dr. James Carter, a cancer policy analyst at the University of London.
Key Takeaways
- Rare cancers account for 20% of cancer cases but receive less than 5% of research funding.
- Initiatives like the NIH’s Rare Diseases Clinical Research Network are increasing investment, but gaps persist.
- Advocates call for policy reforms to ensure equitable funding and treatment access for all cancer patients.
Keep reading